Study of XL784 in Patients With Albuminuria Due to Diabetic Nephropathy

Status Completed

Clinical Trial Summary

This clinical study is being conducted at multiple sites to determine the activity, safety and tolerability of XL784 when given daily to patients with albuminuria due to diabetic nephropathy. XL784 is a small molecule reno-protective metalloproteinase inhibitor, inhibiting both ADAMs (including ADAM10, a target of significant interest because of its important role in blood vessel formation and cell proliferation, and ADAM17/TACE, activation of which has been associated with renal deterioration) and MMPs (including MMP-2 and MMP-9). XL784 was specifically optimized to be MMP-1 sparing, which may be clinically significant because inhibition of MMP-1 has been hypothesized to be associated with musculoskeletal toxicity.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00312780
Study type	Interventional
Source	Symphony Evolution, Inc.
Contact
Status	Completed
Phase	Phase 2
Start date	March 2006
Completion date	December 2007

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04562025` - Clinical Research of UC-MSCs in the Treatment of Diabetic Nephropathy	N/A
Not yet recruiting	`NCT03658317` - Renal Resisitive Index as an Indicator of the Progression of Diabetic Nephropathy	N/A
Recruiting	`NCT02501772` - The Evaluation of Effect of Sanyinjiao (SP6) Acupressure on Early Diabetic Nephropathy	N/A
Completed	`NCT02251067` - Phase 2 Study to Evaluate Safety & Efficacy of VPI-2690B in Diabetic Nephropathy Patients	Phase 2
Completed	`NCT02829177` - Microalbuminuria and Allopurinol in Type 1 Diabetes	Phase 4
Completed	`NCT02276196` - Effect of LIXIsenatide on the Renal System	Phase 4
Completed	`NCT01440257` - A Study to Evaluate the Effect of CCX140-B on Urinary Albumin Excretion in Subjects With Type 2 Diabetes and Albuminuria	Phase 2
Active, not recruiting	`NCT01273675` - An Investigation on the Effect of Candesartan on Early Diabetic Nephropathy	N/A
Terminated	`NCT01129557` - Aldosterone Breakthrough During Diovan, Tekturna, and Combination Therapy in Patients With Proteinuric Kidney Disease	Phase 4
Completed	`NCT00317954` - Spironolactone in Diabetic Nephropathy	Phase 4
Active, not recruiting	`NCT02237352` - Mechanisms of Diabetic Nephropathy in Ecuador
Not yet recruiting	`NCT05061459` - The Expression of circANKRD36 as a New Biomarker of Diabetic Nephropathy
Completed	`NCT01935167` - To Determine the Efficacy and Safety of DW1029M on Microalbuminuria in Patients With Diabetic Nephropathy	Phase 2
Recruiting	`NCT01673204` - Clinical Trial Technology Development for the Validation of Surrogate Prognostic Markers in Patients With Diabetic Nephropathy	Phase 4
Completed	`NCT01726816` - Efficacy and Safety Study of Probucol in Patients With Diabetic Nephropathy	Phase 2
Recruiting	`NCT01458158` - Matrix Metalloproteinases in Atherosclerosis of Chronic Kidney Disease	N/A
Completed	`NCT01476501` - Vitamin D Supplementation in Diabetic Nephropathy	Phase 2
Completed	`NCT01447147` - A Study to Evaluate the Safety and Efficacy of CCX140-B in Subjects With Diabetic Nephropathy	Phase 2
Completed	`NCT01003236` - Evaluating the Renoprotective Effect of Milk Thistle Extract on Patients With Type II Diabetic Nephropathy	Phase 2
Completed	`NCT00535925` - Nephropathy In Type 2 Diabetes and Cardio-renal Events	Phase 4